Loading
A phase 1/2 trial of retlirafusp alfa, rivoceranib (apatinib), gemcitabine and nab-paclitaxel in pancreatic cancer, run by West China Hospital, not yet recruiting.
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC is a phase 1/2, interventional study registered as NCT07802184 by West China Hospital, with a registry enrolment figure of 45 participants, started 2026-09-10 and due to reach its primary completion in 2029-01-01. Interventions recorded: SHR-1701; Apatinib; gemcitabine; Nab-paclitaxel. Conditions listed: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer. Primary outcome: Recommended Phase II Dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "1\) Age 18-75 years, regardless of sex; 2) patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3) previously untreated patients with unresectable locally advanced or metastatic PDAC, with at least one measurable lesion according to RECIST v1". Sites: China. No results are recorded here; the registry entry is the source.
Shares Retlirafusp alfa, Rivoceranib (apatinib), Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.